Attached files
| file | filename |
|---|---|
| 10-Q - FORM 10-Q - SCOLR Pharma, Inc. | form_10-q.htm |
| EX-32.1 - EXHIBIT 32.1 - CEO CERTIFICATION - SCOLR Pharma, Inc. | exhibit_32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - CFO CERTIFICATION - SCOLR Pharma, Inc. | exhibit_31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - CEO CERTIFICATION - SCOLR Pharma, Inc. | exhibit_31-1.htm |
| EX-32.2 - EXHIBIT 32.2 - CFO CERTIFICATION - SCOLR Pharma, Inc. | exhibit_32-2.htm |
| EX-10.6 - EXHIBIT 10.6 - SCOLR Pharma, Inc. | exhibit_10-6.htm |
| EX-10.3 - EXHIBIT 10.3 - SCOLR Pharma, Inc. | exhibit_10-3.htm |
Exhibit
10.4
September
9, 2009
Dr. Bruce
S. Morra
411
11th Ave
West
Kirkland,
WA 98033
bmorra@gmail.com
Dear Dr.
Morra:
Re: Confidential Separation
Agreement dated August 28, 2009 between SCOLR Pharma, Inc. and Bruce Morra (the
“Agreement)
The
purpose of this letter is to correct certain payment amounts set forth in the
Agreement as follows:
Section
2(a)(i) is hereby amended to change the gross sum payable from $222,800 to
$213,176.41:
Section
2(b) is hereby amended to change the amount of the six monthly installment
payments from $35,466.66 to $35,529 each.
Except as
specifically set forth herein, the Agreement shall remain in full force and
effect.
SCOLR
Pharma, Inc.
/s/
Michael Taglich
Michael
Taglich,
Chairman
of the Board
Accepted
and agreed this 9th day of September, 2009
/s/ Bruce S.
Morra
Dr. Bruce
S. Morra